AIMS/HYPOTHESIS: Skin lesions and ulcerations are severe complications of diabetes that often result in leg amputations. In this study we investigated the function of the cytoskeletal protein flightless I (FLII) in diabetic wound healing. We hypothesised that overexpression of FLII would have a negative effect on diabetic wound closure and modulation of this protein using specific FLII-neutralising antibodies (FnAb) would enhance cellular proliferation, migration and angiogenesis within the diabetic wound. METHODS: Using a streptozotocin-induced model of diabetes we investigated the effect of altered FLII levels through Flii genetic knockdown, overexpression or treatment with FnAb on wound healing. Diabetic wounds were assessed using histology, immunohistochemistry and biochemical analysis. In vitro and in vivo assays of angiogenesis were used to assess the angiogenic response. RESULTS: FLII levels were elevated in the wounds of both diabetic mice and humans. Reduction in the level of FLII improved healing of murine diabetic wounds and promoted a robust pro-angiogenic response with significantly elevated von Willebrand factor (vWF) and vascular endothelial growth factor (VEGF)-positive endothelial cell infiltration. Diabetic mouse wounds treated intradermally with FnAb showed improved healing and a significantly increased rate of re-epithelialisation. FnAb improved the angiogenic response through enhanced formation of capillary tubes and functional neovasculature. Reducing the level of FLII led to increased numbers of mature blood vessels, increased recruitment of smooth muscle actin-α-positive cells and improved tight junction formation. CONCLUSIONS/ INTERPRETATION: Reducing the level of FLII in a wound may be a potential therapeutic approach for the treatment of diabetic foot ulcers.
AIMS/HYPOTHESIS: Skin lesions and ulcerations are severe complications of diabetes that often result in leg amputations. In this study we investigated the function of the cytoskeletal protein flightless I (FLII) in diabetic wound healing. We hypothesised that overexpression of FLII would have a negative effect on diabetic wound closure and modulation of this protein using specific FLII-neutralising antibodies (FnAb) would enhance cellular proliferation, migration and angiogenesis within the diabetic wound. METHODS: Using a streptozotocin-induced model of diabetes we investigated the effect of altered FLII levels through Flii genetic knockdown, overexpression or treatment with FnAb on wound healing. Diabetic wounds were assessed using histology, immunohistochemistry and biochemical analysis. In vitro and in vivo assays of angiogenesis were used to assess the angiogenic response. RESULTS:FLII levels were elevated in the wounds of both diabeticmice and humans. Reduction in the level of FLII improved healing of murinediabetic wounds and promoted a robust pro-angiogenic response with significantly elevated von Willebrand factor (vWF) and vascular endothelial growth factor (VEGF)-positive endothelial cell infiltration. Diabeticmouse wounds treated intradermally with FnAb showed improved healing and a significantly increased rate of re-epithelialisation. FnAb improved the angiogenic response through enhanced formation of capillary tubes and functional neovasculature. Reducing the level of FLII led to increased numbers of mature blood vessels, increased recruitment of smooth muscle actin-α-positive cells and improved tight junction formation. CONCLUSIONS/ INTERPRETATION: Reducing the level of FLII in a wound may be a potential therapeutic approach for the treatment of diabetic foot ulcers.
Authors: Wanli Xue; Lu Cai; Yi Tan; Patricia Thistlethwaite; Y James Kang; Xiaokun Li; Wenke Feng Journal: Am J Pathol Date: 2010-06-21 Impact factor: 4.307
Authors: D H Adams; N Ruzehaji; X L Strudwick; J E Greenwood; H D Campbell; R Arkell; A J Cowin Journal: Br J Dermatol Date: 2009-06-09 Impact factor: 9.302
Authors: Marianne Baker; Stephen D Robinson; Tanguy Lechertier; Paul R Barber; Bernardo Tavora; Gabriela D'Amico; Dylan T Jones; Boris Vojnovic; Kairbaan Hodivala-Dilke Journal: Nat Protoc Date: 2011-12-22 Impact factor: 13.491
Authors: Céline M Desmet; Aurore Lafosse; Sophie Vériter; Paolo E Porporato; Pierre Sonveaux; Denis Dufrane; Philippe Levêque; Bernard Gallez Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240
Authors: Zlatko Kopecki; Gink N Yang; Jessica E Jackson; Elizabeth L Melville; Matthew P Calley; Dedee F Murrell; Ian A Darby; Edel A O'Toole; Michael S Samuel; Allison J Cowin Journal: Oncotarget Date: 2015-11-03
Authors: Hannah M Thomas; Parinaz Ahangar; Benjamin R Hofma; Xanthe L Strudwick; Robert Fitridge; Stuart J Mills; Allison J Cowin Journal: Int J Mol Sci Date: 2020-08-05 Impact factor: 5.923